Business Wire · ALNY · October 23, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Get the app for more

Explore stock news, insights and company research.